Overview

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

The DIA 2015 51^st Annual Meeting brings together a global community of life sciences professionals at all levels and across all disciplines all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

The DIA Annual Meeting provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.

Program Committee

Christopher P. Austin, MD CEO Partner
Flagship Pioneering, United States
Michael Rosenblatt, MD Chief Medical Officer
Flagship Pioneering, United States
J. Lynn Bass, PharmD, RPh Senior Director, Medical Science Liaisons
BridgeBio, United States
Daniel Bollag, PhD Chief Strategy Officer
Ocular Therapeutics, United States
Linda Bowen, MSc, RAC Chief of Staff, Oncology Regulatory Strategy
Pfizer, United States
Jonca Bull, MD Vice President, Regulatory Consulting
PPD, United States
Bill Byrom, PhD Vice President, Product Intelligence and Positioning; Principal, eCOA Science
Signant Health , United Kingdom
Joy A. Cavagnaro, PhD President
Access BIO, United States
Karla Childers, MS Head, Bioethics-Based Science and Technology Policy
Johnson & Johnson, United States
Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States
Betsy Fallen, RN Consultant
BAFallen Consulting LLC, United States
Ron Fitzmartin, PhD, MBA Senior Informatics Advisor, Office of Regulatory Operations, CBER
FDA, United States
Michael Folkendt, MS Associate Director for Regulatory Affairs, OPRO, OPQ, CDER
FDA, United States
Elizabeth E. Garrard, PharmD Executive Vice President, Global Safety Operations
Clinipace Worldwide, United States
Jonathan Haddad, MPH HIV Disease Area Head, Clinical Statistics
GlaxoSmithKline, United States
Martin Harvey Allchurch, LLM Head of International Affairs
European Medicines Agency, Netherlands
Jonathan Solomon Helfgott, MS Executive Director, Global Regulatory/Clinical Affairs
Stage 2 Innovations, United States
Deborah J. Henderson, MSN Head, Global Regulatory Policy
Merck & Co., Inc., United States
Rima Izem, PhD Associate Director Statistical Methodology
Novartis, Switzerland
Janet Jenkins-Showalter Head, US Regulatory Policy
Genentech, A Member of the Roche Group, United States
John Kamp Washington Counsel
Coalition For Healthcare Communication (CHC), United States
Ellen Kelso Head, Knowledge Strategy
KSE Ltd., United States
Lynn King, MHA Chief Operating Officer
M3 Wake Research, Inc, United States
Agnes Klein, MD Senior Medical Advisor
Health Canada, Canada
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States
Mark Kryah, PMP Executive Director, Program Team Leader, Program and Portfolio Management
Ultragenyx Pharmaceutical Inc., United States
JeanMarie Markham Chief Executive Officer
Clinlogix, United States
Philomena McArthur, JD VP, Global Policies, Procedures & Training, Health Care Compliance & Privacy
Johnson & Johnson International, United States
Ann Meeker-O'Connell, MS Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC
FDA, United States
Jon Meyer, MBA, MSc Co-Founder and Managing Member
Life Science Strategy Group, LLC, United States
Mary Murray, MBA, MS Family Caregiver
Independent Consultant, United States
Bob Muzerall Vice President, Sales & Sales Training
AMPLEXOR Life Sciences, LLC, United States
Nancy Bradish Myers, JD CEO and Founder
Catalyst Healthcare Consulting, Inc, United States
Jane Elizabeth Myles, MSc Program Director
Decentralized Trials and Research Alliance (DTRA), United States
Roger Nosal, PhD Vice President, Head of Global CMC
Pfizer Inc, United States
Lisa Palladino-Kim, MS Program Director / Lecturer
Rutgers School of Health Professions Clin Research Mgmt, United States
Pradip Paul, MD, MS Consultant
Strategic Pharmacovigilance and Risk Management, United States
Kirsten H. Paulson, MS, RAC
Pfizer, Inc., United States
Julia Petses, PharmD Global Head, Medical Information Excellence and SEC Established and Rare Franchi
Novartis, United States
Christine Pierre, RN President
Society for Clinical Research Sites, United States
James E. Polli, PhD Prof, Ralph F Shangraw/Noxell Endowed Chair in Industrial Pharmacy/Pharmaceutic
University of Maryland School of Pharmacy, United States
Sarah Pope Miksinski, PhD Executive Director, CMC Regulatory Affairs
Gilead Sciences, United States
Badri Rengarajan, MD Life Sciences
Jazz Pharmaceuticals, United States
Matthew D. Rotelli, PhD, MS Vice President, Bioethics
Eli Lilly and Company, United States
Leslie Sam President
Leslie Sam and Associates, LLC, United States
Abdul J. Sankoh, PhD, MA, MS Vice President, Data Science
Sage Therapeutics, Inc. , United States
Suzanne Sensabaugh, MBA, MS President and Principal Consultant
HartmannWillner LLC, United States
Ashley F. Slagle, PhD, MS Principal, Scientific and Regulatory Consulting
Aspen Consulting, LLC, United States
Nancy Pire Smerkanich, DrSc, MS Assistant Professor Regulatory & Quality Sciences
University of Southern California School of Pharmacy, United States
Maureen Smith Patient Advocate / Secretary
Canadian Organization For Rare Disorders (CORD), Canada
William B. Smith, MD CEO
Alliance for Multispecialty Research, LLC , United States
Ling Su, PhD Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China
Sameer Thapar, PharmD, RPh Global Pharmacovigilance Director
Oracle Health Sciences, United States
Toshiyoshi Tominaga, PhD Project Professor
Keio University Hospital, Japan
Linda Fossati Wood President
MedWrite, Inc., United States